SUMMARY

oxygen

**MEDICINAL OXYGEN AIR
LIQUIDE SANTE FRANCE
200 bar**

inhalation gas in cylinders

Inclusion on list: First listing

Range supplements

Adopted by the Transparency Committee on 28 August 2024

Summary of opinion

Favourable opinion for reimbursement for:

- Correction of hypoxia of various aetiologies requiring normobaric or hyperbaric oxygen therapy,
- Supply of ventilators in anaesthesia or intensive care,
- Use as a carrier for inhaled medicinal products in nebuliser therapy,
- Treatment of acute attacks of cluster headache.

No clinical added value of the new forms compared to the forms already available.

This document and its bibliographic reference are available to download at www.has-sante.fr

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – August 2024

Transparency Committee's conclusions

Clinical Benefit

- The conditions concerned are serious, incapacitating (cluster headaches) and can be life-threatening.
- The proprietary medicinal product OXYGEN AIR LIQUIDE SANTE FRANCE 200 bar inhalation gas, is a symptomatic medicinal product.
- The efficacy/adverse effects ratio is high.
- There are alternatives, which are the other proprietary medicinal products containing medicinal oxygen 200 bar inhalation gas, in all the MA indications.

Treatment with medicinal oxygen maintains its role in the care pathway in the indications validated by the MA aimed at correcting hypoxaemia (defined by $\text{SpO}_2 < 90\%$ and/or a $\text{PaO}_2 < 60 \text{ mmHg}$). **The Committee highlights the fact that medicinal oxygen is a medicinal product that can have adverse effects. Therefore, oxygen therapy must be monitored appropriately.**

→ Public health benefit

MEDICINAL OXYGEN AIR LIQUIDE SANTE FRANCE 200 bar inhalation gas, has no additional public health benefit compared to the forms already listed.

The Committee considers that the clinical benefit of these new forms of the medicinal product MEDICINAL OXYGEN AIR LIQUIDE SANTE FRANCE 200 bar inhalation gas, is high in the MA indications.

The Committee issues a favourable opinion for inclusion in the list of covered drugs for in-patients approved for use in the indications and at the MA dosages.

Clinical Added Value

This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed.